Drug development company Nyrada (ASX:NYR) has completed a dog cardiovascular study which is providing ongoing data to support safety and tolerability of its lead Brain Injury drug candidate NYR-BI03.
Nyrada is developing NYR-BI03, a first in class neuroprotection treatment for both stroke and traumatic brain injury (TBI). In February 2024, the company reported preclinical stroke study results showing NYR-BI03 provided a statistically significant level of neuroprotection, rescuing 42% of brain injury in the penumbra region in treated animals.
Nyrada’s dog cardiovascular study assessed the effects of NYR-BI03 on heart function, blood pressure, and overall cardiovascular health via ECG. Coupled with the earlier hERG study, this dog cardiovascular study completes the regulatory cardiac safety profiling of NYR-BI03 necessary to commence a Phase I study.
Remaining brain injury programme GLP studies will be analysed and reported as they become available.
Subject to satisfactory completion of all GLP studies, Nyrada will submit a Human Research Ethics Application with the expectation of commencing its first in human Phase I clinical trial in late 2QFY2025 (quarter ending December 2024).
